Migden, Michael R, Carola Berkin, Anne Lynn Chang, and Et al. 2018. “Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine 2 (December):S77. https://doi.org/10.25251/skin.2.supp.77.